

Date: 23 July, 2024

To,

Corporate Relationship Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, **Mumbai-400 001**

Dear Sir/Madam,

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor, Plot No.C/1, G Block Bandra Kurla Complex, Bandra (E) **Mumbai-400 051**

Shilpa Pharma Lifesciences Limited, Unit 2, Raichur, Karnataka has cleared the COFEPRIS-Mexico GMP inspection

This is to inform you that the Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited's Active Pharmaceutical Ingredient (API) manufacturing facility, Unit II, situated at Raichur in Karnataka state has undergone a GMP inspection by COFEPRIS-Mexico from November 6-10, 2023.

Following a successful inspection, the Unit has been issued GMP Certification from COFEPRIS-Mexico

The facility is involved in manufacturing various oncology and nononcology APIs. The company remains commit ted to maintain the GMP status and quality standards as per the expectations and standards of Global Regulatory Authorities.

For SHILPA MEDICARE LIMITED

Ritu Tiwary
Company Secretary & Compliance Officer